MAIA Biotechnology宣布在Thio-104三期关键试验中首次为患者使用Ateganosine,作为晚期非小细胞肺癌的三线治疗。
MAIA Biotechnology宣布在Thio-104三期关键试验中首次为患者使用Ateganosine,作为晚期非小细胞肺癌的三线治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.